Qtron Investments LLC Acquires 3,781 Shares of Gilead Sciences, Inc. $GILD

Key Points

• Qtron Investments LLC increased its holdings in Gilead Sciences, Inc. by 35.7% in the 1st quarter, acquiring an additional 3,781 shares and valuing their total investment at approximately $1.61 million.
• Gilead Sciences announced a quarterly dividend of $0.79 per share, with a yield of 2.7%, set to be paid on September 29th to investors of record on September 15th.
• The company reported earnings of $2.01 per share, exceeding estimates, with revenue of $7.08 billion for the quarter, which is a 1.4% increase year-over-year.

Qtron Investments LLC increased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 35.7% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 14,375 shares of the biopharmaceutical company's stock after buying an additional 3,781 shares during the quarter. Qtron Investments LLC's holdings in Gilead Sciences were worth $1,611,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Smallwood Wealth Investment Management LLC bought a new stake in shares of Gilead Sciences during the 1st quarter worth $25,000. Goodman Advisory Group LLC bought a new stake in shares of Gilead Sciences during the 1st quarter worth $29,000. Core Alternative Capital lifted its position in shares of Gilead Sciences by 370.8% during the 1st quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock worth $34,000 after buying an additional 241 shares during the last quarter. IMA Advisory Services Inc. bought a new stake in shares of Gilead Sciences during the 1st quarter worth $39,000. Finally, Financial Network Wealth Advisors LLC raised its position in Gilead Sciences by 538.6% in the first quarter. Financial Network Wealth Advisors LLC now owns 364 shares of the biopharmaceutical company's stock valued at $41,000 after purchasing an additional 307 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Trading Down 0.5%

NASDAQ GILD opened at $118.37 on Monday. The business has a 50 day simple moving average of $111.88 and a 200 day simple moving average of $108.50. Gilead Sciences, Inc. has a one year low of $72.89 and a one year high of $121.83. The stock has a market capitalization of $146.87 billion, a P/E ratio of 23.58, a P/E/G ratio of 0.73 and a beta of 0.33. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping the consensus estimate of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%. The business had revenue of $7.08 billion during the quarter, compared to analysts' expectations of $6.95 billion. During the same quarter last year, the firm posted $2.01 earnings per share. The firm's revenue was up 1.4% on a year-over-year basis. Research analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, September 29th. Investors of record on Monday, September 15th will be paid a dividend of $0.79 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $3.16 annualized dividend and a yield of 2.7%. Gilead Sciences's dividend payout ratio (DPR) is currently 62.95%.

Insiders Place Their Bets

In other Gilead Sciences news, CEO Daniel Patrick O'day sold 10,000 shares of the firm's stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $113.94, for a total value of $1,139,400.00. Following the completion of the sale, the chief executive officer owned 605,725 shares of the company's stock, valued at approximately $69,016,306.50. This trade represents a 1.62% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Johanna Mercier sold 3,000 shares of the firm's stock in a transaction that occurred on Tuesday, July 15th. The shares were sold at an average price of $111.03, for a total value of $333,090.00. Following the completion of the sale, the insider directly owned 117,168 shares of the company's stock, valued at $13,009,163.04. This trade represents a 2.50% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 79,500 shares of company stock worth $8,734,625. Company insiders own 0.27% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have commented on GILD. Oppenheimer dropped their target price on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a research report on Friday, April 25th. Needham & Company LLC upgraded Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 target price for the company in a research report on Friday, July 25th. Royal Bank Of Canada increased their target price on Gilead Sciences from $96.00 to $98.00 and gave the company a "sector perform" rating in a research report on Friday, August 8th. Cantor Fitzgerald began coverage on Gilead Sciences in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 target price for the company. Finally, UBS Group increased their target price on Gilead Sciences from $108.00 to $112.00 and gave the company a "neutral" rating in a research report on Friday, August 8th. Seven investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $114.82.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.